Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826756 | 0.92 | HDAC1 (0.36) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL1114600 | 0.90 | CASP3 (0.44) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL3246836 | 0.90 | CASP3 (0.39) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL8390987 | 0.89 | HDAC1 (0.43) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL13447661 | 0.88 | TSHR (0.39) | — | |
| SCHEMBL3243751 | 0.87 | HDAC1 (0.42) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL1114381 | 0.86 | HDAC1 (0.41) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL1114380 | 0.85 | HDAC1 (0.47) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL1114740 | 0.84 | TRPM8 (0.42) | HDAC1HDAC6HDAC5HDAC8CASP3 | |
| SCHEMBL3242548 | 0.84 | SMN1; SMN2 (0.49) | HDAC1HDAC6HDAC5HDAC8CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | claimed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | claimed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2278879-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| WO-2009131957-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | HDAC1 2458/4885HDAC6 829/4885HDAC5 2697/4885 |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | HDAC1 2122/4885HDAC6 636/4885HDAC5 2615/4885 |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | HDAC1 2122/4885HDAC6 636/4885HDAC5 2615/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | HDAC1 2458/4885HDAC6 829/4885HDAC5 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.